🔵Novavax wanes less over time, and provides meaningful protection against actual infection.
Study 1:
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial:
sciencedirect.com/science/ar…
This study found that priming series of Novavax induced persistent immune responses up to 1 year after the second dose.
Study 2:
Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea:
sciencedirect.com/science/ar…
Novavax performed better than the Pfizer vaccine for preventing lab-confirmed SARS-CoV-2 infection. Novavax has an aHR of 0.78 after the third dose and 0.86 after the fourth dose, meaning it was 14% to 22% better at preventing infection.
Study 3:
Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents:
pubmed.ncbi.nlm.nih.gov/4086…
This is the same type of study as the previous one, except this time, it was conducted in an adolescent population. Once again, it found that Novavax performed better than the Pfizer vaccine. Novavax had an aHR of 0.57 for a priming series and 0.68 for a booster dose, meaning it was 32% to 43% better at preventing infection:
Study 4:
Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany:
mdpi.com/2076-393X/12/4/387
Within the 10 months after receiving Novavax, there was a 95% reduction in the amount of doctor’s visits associated with COVID-19 diagnosis.
🔵Additional Novavax doses shrink the antigenic range. This means that the breadth of protective antibodies, against additional and future variants, increases.
Study:
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373:
nejm.org/doi/full/10.1056/NE…
This study found that “Boosting with Novavax resulted in enhanced cross-reactive immunity to SARS-CoV-2 variants, a decreased gap between immune recognition of the variants and the ancestral strain, and the induction of a potentially more universal-like response against SARS-CoV-2 variants.”
🔵Novavax provides better protection in the upper respiratory tract, which is extremely important when trying to avoid infections in general, long covid, and translocation to the brain & lower respiratory tract:
Study 1:
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates:
pmc.ncbi.nlm.nih.gov/article…
Novavax blunted virus replication and showed a significant reduction in viral load in the airway early post-infection, at days 2 and 4. Conversely, the mRNA shot offered only limited protection at days 2 and 4, and took longer to “catch up”.
Study 2:
Detection of anti–SARS-CoV-2 mucosal IgA in clinical saliva samples after a dose of Novavax COVID-19 vaccine:
medrxiv.org/content/10.1101/…
Salivary samples collected 28 days after vaccination showed a significant increase in anti-SARS-CoV-2 spike antibodies.
For this study, it’s notable Novavax actually had to develop their own test to establish a way to test for mucosal IgA, because we didn't have one before, because we never needed one, because no vaccines in the past have even came close to providing this level of mucosal immunity. Let that sink in.
2/4